Lantern Pharma (LTRN) Tops Q2 EPS by 5c

Lantern Pharma (NASDAQ: LTRN) reported Q2 EPS of ($0.21), $0.05 better than the analyst estimate of ($0.26). Revenue for the quarter came in at $0 , versus $0 reported last year.

For earnings history and earnings-related data on Lantern Pharma (LTRN) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Wintermar acquires full control of Fast Offshore Supply, adding 5 new CTVs
• C.H. Robinson acquires DeSpir Logistics for $75 million